4559:TYO
Zeria Pharmaceutical Co Ltd
JP¥ 2.088,00
arrow_upward
+0,19%(+4,00) 1D
13 de nov., 15:30:00 GMT+9 · JPY
search
Todos os ativos
| Códigos | Preço | Variação | % de variação |
|---|
insights_autoGerando os principais insights para 4559…
Abrir
JP¥ 2.078
Alta
JP¥ 2.105
Baixa
JP¥ 2.067
Valor de mercado
104,65 bi
Volume médio
145,41 mil
Volume
90,60 mil
Dividendo
2,39%
Dividendo trimestral
JP¥ 12
Data de ex-dividendo
30 de mar. de 2027
Índice P/L
8,62
Alto — 52 sem
JP¥ 2.434
Baixo — 52 sem
JP¥ 1.895
LPA
JP¥ 242
Ações em circulação
50,11 mi
Nº de funcionários
2 mil
Abrir
JP¥ 2.078
Alta
JP¥ 2.105
Baixa
JP¥ 2.067
Valor de mercado
104,65 bi
Volume médio
145,41 mil
Volume
90,60 mil
Dividendo
2,39%
Dividendo trimestral
JP¥ 12
Data de ex-dividendo
30 de mar. de 2027
Índice P/L
8,62
Alto — 52 sem
JP¥ 2.434
Baixo — 52 sem
JP¥ 1.895
LPA
JP¥ 242
Ações em circulação
50,11 mi
Nº de funcionários
2 mil
Notícias
De fontes da web e parceiros de notícias
qz.com
·
há 7 horas
How much of the S&P 500 is Nvidia? Concentration explained
marketscreener.com
·
há 7 horas
S&P 500 Posts Weekly Gain as Energy Sector Leads Broad Climb
TradingView
·
há 5 horas
S&P 500, Dow, Nasdaq End Lower Amid Nvidia Turmoil, But Record Best Week Since August — SPCX, NVDA, ARM, AZN In Focus
Investing.com
·
há 7 horas
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.10%
Perfil
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
Sobre Zeria Pharmaceutical Co Ltd
CEOSachiaki Ibe
Funcionários1,75 mil
Data de fundação22 de dez. de 1955
Sede-
SetorHealth Care
Setor-
Sitezeria.co.jp